RxSight Valuation Multiples

RxSight Overview

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Founded

1997

HQ

Employees

498

Website

rxsight.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $134M

EBITDA: ($47M)

EV

$63M

Valuation Multiples

Multiples.vc

Start free trial

RxSight Financials

RxSight reported last 12-month revenue of $134M and negative EBITDA of ($47M).

In the same LTM period, RxSight generated $101M in gross profit, ($47M) in EBITDA losses, and had net loss of ($43M).

RxSight P&L

In the most recent fiscal year, RxSight reported revenue of $134M and EBITDA of ($36M).

RxSight expects next 12-month revenue of XXX and NTM EBITDA of XXX

RxSight Stock Performance

RxSight has current market cap of $280M, and enterprise value of $63M.

RxSight's stock price is $6.78.

RxSight Valuation Multiples

RxSight trades at 0.5x EV/Revenue multiple, and (1.3x) EV/EBITDA.

RxSight Financial Valuation Multiples

As of April 11, 2026, RxSight has market cap of $280M and EV of $63M.

Equity research analysts estimate RxSight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

RxSight has a P/E ratio of (6.5x).

RxSight Margins & Growth Rates

RxSight's revenue in the last 12 month grew by 1%.

RxSight's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

RxSight's rule of 40 is (42%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RxSight's rule of X is (46%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

RxSight Public Comps

See public comps and valuation multiples for other Medical Devices comps.

RxSight M&A Activity

RxSight acquired XXX companies to date.

Last acquisition by RxSight was on XXXXXXXX, XXXXX. RxSight acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

RxSight Investment Activity

RxSight invested in XXX companies to date.

RxSight made its latest investment on XXXXXXXX, XXXXX. RxSight invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).